Image: Group therapy: Genetic differences affect how patients respond to monoclonal-antibody therapies. PIKAMAB believes that it can sort patients into specific groups and tailor treatments accordingly. Credit: Technology Review From Technology Review:
A company wants to improve monoclonal-antibody therapies by tailoring them to patients' genotypes.
Monoclonal antibodies, which are engineered to hone in on very specific biological targets, have taken off therapeutically in recent years: several are now approved for treating cancers and autoimmune diseases, and nearly 200 are in clinical trials. But one of the challenges of monoclonal-antibody therapy is the fact that some people respond very well to the drugs while others respond only moderately or not at all.
A startup called PIKAMAB, based in Menlo Park, CA, believes that it can make monoclonal antibodies more effective by grouping patients together based on their genotype and offering a customized antibody developed for that genotype. The company hopes that this "stratified" approach to drug development and treatment will help drug companies achieve better results.
Read more ....
1 comment:
Hello,
Very good site you have created. Monoclonal antibody drugs are specifically designed to attack cancer cells while minimizing harm to healthy cells, which has become an important tool in biochemistry, molecular biology. Thanks a lot for creating this type of valuable site.....
Post a Comment